InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,208.40
(
-0.26%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.77
(
-0.28%
)
Bitcoin
63,606.68
(
-1.87%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: rurik post# 32376

Thursday, 07/18/2013 11:22:09 PM

Thursday, July 18, 2013 11:22:09 PM

Post# of 80490
It says for "Interim analysis of PK and toxicity data".

But could be a bad sign since trial since update was from February. Likely a safety concern, Dovitinib seems to have a poor safety profile (see link) and if combined with a typical EGFR rash then that would just about kill it.

http://jco.ascopubs.org/content/29/12/e340.full


Note '113 reported no rash at ASCO, Pona reports 5% Grade 3/4 on the label.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up